Ariceum Therapeutics Commences Phase 1 Clinical Trial in Patients with Recurrent Glioblastoma ...Middle East

PR Newswire - News
Novel iodine radiolabelled PARP inhibitor (rPARPi) entering clinical development in Phase 1 trial to assess safety and early efficacy Dose escalation study followed by expansion cohorts in recurrent glioblastoma with potential to move into primary glioblastoma BERLIN, July 25, 2024...

Hence then, the article about ariceum therapeutics commences phase 1 clinical trial in patients with recurrent glioblastoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ariceum Therapeutics Commences Phase 1 Clinical Trial in Patients with Recurrent Glioblastoma )

Apple Storegoogle play

Last updated :

Also on site :